INHERENT RESISTANCE IN REFRACTORY METASTATIC COLORECTAL CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES

被引：0
|
作者：
Galal, K. [1 ]
Zaghloul, K. [2 ]
Mourad, M. A. [3 ]
机构：
[1] Cairo Univ, Dept Oncol, Cairo, Egypt
[2] Tanta Univ, Dept Internal Med, Tanta, Egypt
[3] Assiut Univ, Dept Radiol, Assiut, Egypt
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [41] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Saltz, LB
    Meropol, NJ
    Loehrer, PJ
    Needle, MN
    Kopit, J
    Mayer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1201 - 1208
  • [42] The epidermal growth factor receptor as a target for colorectal cancer therapy
    Lockhart, C
    Berlin, JD
    SEMINARS IN ONCOLOGY, 2005, 32 (01) : 52 - 60
  • [43] Trichomegaly of the eyelashes induced by the epidermal growth factor receptor inhibitor cetuximab in the treatment of metastatic colorectal cancer
    Matos, Leonor Vasconcelos
    Pissarra, Ana
    Malheiro, Mariana
    Placido, Ana Neto
    BMJ CASE REPORTS, 2019, 12 (04)
  • [44] Relationship Between Colorectal Cancer Biomarkers and Response to Epidermal Growth Factor Receptor Monoclonal Antibodies Reply
    Bardelli, Alberto
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : E532 - E533
  • [45] Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
    Liu, Jiang
    Hu, Jing
    Cheng, Lei
    Ren, Wei
    Yang, Mi
    Liu, Baorui
    Xie, Li
    Qian, Xiaoping
    ONCOTARGETS AND THERAPY, 2016, 9 : 557 - 565
  • [46] PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
    Prenen, Hans
    De Schutter, Jef
    Jacobs, Bart
    De Roock, Wendy
    Biesmans, Bart
    Claes, Bart
    Lambrechts, Diether
    Van Cutsem, Eric
    Tejpar, Sabine
    CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3184 - 3188
  • [47] Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients
    Segelov, E.
    Earle, C.
    Venook, A. P.
    Saskin, R.
    Mofid, L.
    Singh, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer
    Martini, G.
    Belli, V.
    Vitiello, P. P.
    Troiani, T.
    Cardone, C.
    Napolitano, S.
    Matrone, N.
    Sforza, V.
    Savastano, B.
    Renato, F.
    Morgillo, F.
    Della Corte, C. M.
    Ciardiello, D.
    Giunta, E. F.
    De Falco, V.
    Zanaletti, N.
    Vitale, P.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer
    Matsuhashi, Nobuhisa
    Takahashi, Takao
    Matsui, Satoshi
    Tanahashi, Toshiyuki
    Imai, Hisashi
    Tanaka, Yoshihiro
    Yamaguchi, Kazuya
    Yoshida, Kazuhiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (05) : 1391 - 1400
  • [50] Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?
    Marshall, John L.
    JOURNAL OF ONCOLOGY, 2009, 2009
12345